Container closure integrity (CCI) is essential to maintaining the integrity of sterile pharmaceutical products and protecting patient safety throughout their lifecycle.

However, deep-cold storage conditions can increase the risk of temporary CCI failures, which may not be detected by conventional methods such as blue dye testing.

To investigate molded glass vial CCI performance at -80°C, SGD Pharma partnered with Lighthouse Instruments, a specialist in container closure integrity testing with more than 20 years of scientific experience.

Why Container Closure Integrity Matters at Deep-Cold Temperatures

Maintaining container closure integrity during ultra-low temperature storage is particularly important for sensitive pharmaceutical formulations.

While extensive research has examined the CCI performance of tubular glass vials under low-temperature conditions, comparatively less data are available for molded glass vials.

This gap is significant given the mechanical strength, chemical durability and suitability of molded glass for sensitive pharmaceutical applications.

Evaluating Molded Glass Vials at -80°C

SGD Pharma and Lighthouse Instruments conducted a study to assess the performance of molded glass vials stored at -80°C.

The evaluation combined two complementary analytical techniques:

  • Laser-based headspace analysis, used to detect temporary container closure integrity defects.
  • Residual seal force (RSF) measurements, used to assess seal integrity under deep-cold storage conditions.

Together, these methods provided insight into the performance of the vial closure system during ultra-low temperature storage.

Study Findings: Robust CCI Performance Under Deep-Cold Conditions

The study demonstrated that molded glass vials, like tubular glass vials, can maintain robust container closure integrity during ultra-low temperature storage.

The findings also highlight the importance of combining analytical seal quality testing with laser-based headspace analysis to evaluate CCI performance.

This combined approach can provide valuable information for pharmaceutical manufacturers when assessing packaging systems for temperature-sensitive products.

Supporting Pharmaceutical Packaging Selection and Validation

Understanding container closure integrity under deep-cold conditions is essential when selecting packaging for sensitive pharmaceutical formulations.

The findings from this collaborative study can support:

  • Selection of suitable packaging components.
  • Pharmaceutical process validation.
  • Development of comprehensive CCI control strategies.
  • Evaluation of glass vial performance for cold-chain pharmaceutical applications.

By contributing additional scientific data on molded glass vial performance, the study helps expand the knowledge available to pharmaceutical manufacturers.

Read the Full Study

Discover the complete findings from the SGD Pharma and LIGHTHOUSE Instruments collaboration, including the analytical methods used to evaluate molded glass vial CCI under deep-cold storage conditions.